Get startedLog in
    Picture of Egetis Therapeutics AB (publ) logo

    EGTX — Egetis Therapeutics AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    All News

    Brief: Egetis Completes U.S. Rolling NDA Submission For Emcitate

    Picture of Egetis Therapeutics AB (publ) logoEgetis Therapeutics AB (publ)
    29/01/2026 06:13
    Jan 29 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

COMPLETES THE U.S. ROLLING NDA SUBMISSION FOR EMCITATE® (TIRATRICOL) FOR TREATMENT OF MCT8 DEFICIENCY

ANTICIPATES REGULATORY DECISION ON NDA APPLICATION IN SEPTEMBER 2026

Source text: ID:nMFNbj5Flg

Further company coverage: EGTX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

    Recent news on Egetis Therapeutics AB (publ)

    See all news